ARUP Consult®, a free source of laboratory testing information for clinicians, released several new and updated resources in August. |
September 6, 2023 |
ARUP Consult Updates Testing Resources for Osteoporosis, Immunobullous Diseases, and Epilepsy ARUP Consult, a free source of expert guidance in laboratory testing, has released updated |
ARUP Consult®, a free source of laboratory testing information for clinicians, released several new and updated resources in July. |
August 2, 2023 |
ARUP Consult Updates Lyme Disease, Pneumonia, and Infertility Testing Resources ARUP Consult, a free source of expert guidance in laboratory testing, has released updated |
ARUP Consult®, a free source of laboratory testing information for clinicians, has updated several resources in June. |
July 6, 2023 |
ARUP Consult Updates Human Papillomavirus, Chronic Lymphocytic Leukemia, and Amenorrhea Resources ARUP Consult, a free source of expert guidance in laboratory testing, has updated resources on |
ARUP’s new test is the first companion diagnostic immunoassay for a gene therapy product to receive FDA approval. FDA has issued simultaneous approval of ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), BioMarin’s gene therapy for severe hemophilia A. |
June 29, 2023 |
ARUP Laboratories has received FDA approval for its companion diagnostic immunoassay, |
ARUP Laboratories’ Access and Reimbursement Manager Valerie Collier, MS, CGC, will be featured as an expert panelist in a special upcoming Dark Report webinar on June 29. |
June 23, 2023 |
ARUP Expert to Present Insights on Obtaining Z-Codes in Special Dark Report… Valerie Collier, MS, CGC, will present insights on the DEX MolDx program and how to submit |
ARUP President and Chief Scientific Officer Tracy I. George, MD, pioneered the central pathology review service that screens and confirms potential patient candidates for clinical trials and monitors their drug responses. |
June 12, 2023 |
ARUP’s Clinical Trials Support Leads to First FDA-Approved Drug for Indolent Systemic… ARUP’s Clinical Trials and PharmaDx groups supported Blueprint Medicines’ clinical trials |